Teva Pharmaceutical Industries Ltd., a leading generic pharmaceutical company, (NYSE and TASE: TEVA) announced that it is working with Honeywell (NASDAQ: HON) to help reduce energy consumption and carbon emissions at its Debrecen, Hungary, manufacturing facility.
Teva will leverage Honeywell’s ‘Energy as a Service’ (EaaS) model, enabling it to deploy energy improvement upgrades without making a major capital investment.
The efforts will support Teva in furthering its environmental, social and governance goals and minimize its impact on the environment.
Under the EaaS contract, Honeywell will establish a three-year energy performance baseline for the Debrecen facility and determine what building assets are driving the site’s energy consumption.
Using Ready-now solutions such as Honeywell Forge Sustainability+ for Buildings | Carbon and Energy Management and submetering tools, Honeywell will enable continuous collection of energy use data at the device and asset level.
Using this data, Honeywell will work with Teva to develop a plan to help reduce energy use while maintaining an ideal occupant experience.
Gary Baker, general manager, Teva Active Pharmaceutical Ingredients, Hungary Said :
The urgency of building better energy management is paramount.
Commercial buildings and construction accounted for 37% of global energy- and process-related carbon dioxide emissions and more than 34% of energy demand globally 2011.
Evangelos Alepochoritis, European leader for energy and sustainability, Honeywell said :
Honeywell’s EaaS approach can help customers meet their sustainability goals by implementing a variety of upgrades throughout a building to help reduce energy use.
Honeywell is also creating an ecosystem of third-party solutions and complementary services to further help customers reduce energy consumption in their buildings.
About Teva
Teva Pharmaceutical Industries Ltd. has been developing and producing medicines to improve people’s lives for more than a century.
We are a global leader in generic and innovative medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area.
Around 200 million people around the world take a Teva medicine every day and are served by one of the largest and most complex supply chains in the pharmaceutical industry.
Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of innovative medicines and biopharmaceutical products.
About Honeywell
Honeywell delivers industry specific solutions that include aerospace products and services; control technologies for buildings and industry; and performance materials globally.
Our technologies help aircraft, buildings, manufacturing plants, supply chains, and workers become more connected to make our world smarter, safer, and more sustainable.